A randomized, single-blinded trial of a tripeptide/hexapeptide healing regimen following laser resurfacing of the face.
A topical healing system containing a combination of active ingredients including a tripeptide and hexapeptide (TriHex Technology™) has been found to stimulate neoelastogenesis and neocollagenesis. Evaluate the use of the tripeptide/hexapeptide topical system following fractionated CO2 laser resurfacing compared to a bland ointment and cream. In this single-blinded, randomized study, 15 female subjects aged 45-70 years underwent laser resurfacing of the face. Subjects were randomized to use of the tripeptide/hexapeptide system (n=10) or a bland dimethicone-based ointment and petrolatum-based cream (n=5) from 3 weeks pre- until 12 weeks postprocedure. A blinded investigator graded erythema, edema, crusting, exudation, and healing on postprocedure days 1, 3, 4, 7, 28, and 84. A photodamage/wrinkle scale was completed on days 28 and 84. Subjects performed symptomatology grading on days 1 through 14 and completed self-assessments at days 28 and 84. Data from 14 subjects were analyzed. Blinded-investigator-rated healing was better for the tripeptide/hexapeptide system, reaching statistical significance at day 7. The tripeptide/hexapeptide group demonstrated less erythema and exudation during the first postprocedure week, reaching significance at day 3. On days 1 through 14, subjects using the tripeptide/hexapeptide system reported less tenderness and burning/stinging, also reaching significance on day 3. At day 84, subjects using the tripeptide/hexapeptide system reported higher satisfaction and were more likely to recommend the treatment to others. Postresurfacing use of a tripeptide/hexapeptide system proved effective and well-tolerated. Subject satisfaction was greater among those using this system, which may indicate an improved patient experience following laser resurfacing.